Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

Abstract

Objective: To generate evidence on the longer term cost effectiveness of disease modifying treatments in patients with relapsing-remitting multiple sclerosis.

Design: Prospective cohort study with historical comparator.

Setting: Specialist multiple sclerosis clinics in 70 centres in the United Kingdom.

Participants: Patients with relapsing-remitting multiple sclerosis who started treatment from May 2002 to April 2005 under the UK risk sharing scheme.

Interventions: Treatment with interferon beta or glatiramer acetate in accordance with guidelines of the UK Association of British Neurologists.

Main outcome measures: Observed utility weighted progression in disability at two years' follow-up assessed on the expanded disability status scale (EDSS) compared with that expected by applying the progression rates in a comparator dataset, modified for patients receiving treatment by multiplying by the hazard ratio derived separately for each disease modifying treatment from the randomised trials.

Results: In the primary per protocol analysis, progression in disability was worse than that predicted and worse than that in the untreated comparator dataset ("deviation score" of 113%; excess in mean disability status scale 0.28). In sensitivity analyses, however, the deviation score varied from -72% (using raw baseline disability status scale scores, rather than applying a "no improvement" algorithm) to 156% (imputing missing data for year two from progression rates for year one).

Conclusions: It is too early to reach any conclusion about the cost effectiveness of disease modifying treatments from this first interim analysis. Important methodological issues, including the need for additional comparator datasets, the potential bias from missing data, and the impact of the "no improvement" rule, will need to be addressed and long term follow-up of all patients is essential to secure meaningful results. Future analyses of the cohort are likely to be more informative, not least because they will be less sensitive to short term fluctuations in disability.

Fig 1 Participants with relapsing-remitting multiple sclerosis (RRMS) taking disease modifying treatments (DMT) in multiple sclerosis risk sharing scheme. *Data used for supplementary analyses. †Patients assessed as secondary progressive multiple sclerosis (SPMS) at year 1 follow-up; their EDSS scores for year 1 (but not for later years) retained in primary analysis

Fig 2 Expected and observed EDSS at follow-up for per protocol analysis

Fig 3 Effect of baseline adjustment of EDSS